≡ Risteys
R13

Documentation Changelog GitHub Contact & Feedback
info icon

This is a non-core endpoint: only basic statistics are computed.

Malignant neoplasm of ureter

DOID Endpoint Browser

C3_URETER

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519972

1. Apply sex-specific rule

None

519972

2. Check conditions

None

519972

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Cause of death: ICD-10 — C66
  • Cause of death: ICD-9 — 189[2-3]
  • Cause of death: ICD-8 — 1892
  • Cancer registry: Topography ICD-O-3 — C66
  • Cancer registry: Morphology ICD-O-3 — ANY
  • Cancer registry: Behaviour codes — 3

2 out of 7 registries used, show all original rules.

92

4. Check minimum number of events

None

92

5. Include endpoints

None

92

6. Filter based on genotype QC (FinnGen only)

85

Control definitions (FinnGen only)

Control exclude
C3_CANCER, C3_CANCER_WIDE

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF9

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

-FinnGen-

Key figures

All Female Male
Number of individuals 85 32 53
Unadjusted period prevalence (%) 0.02 0.01 0.02
Median age at first event (years) 73.81 73.22 74.17

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
92
Matched controls
920
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C66
ICD-10 Finland
Malignant neoplasm of ureter
+∞
100.1
77
*
8120/3-C66.9
ICD-O-3
Transitional cell carcinoma, NOS, of ureter
+∞
89.9
71
*
UKC02
NOMESCO Finland
Cystoscopy
72.1
78.9
82
94
R31
ICD-10 Finland
Unspecified haematuria
21.7
52.3
58
67
C67.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of bladder
+∞
43.2
38
*
UKB02
NOMESCO Finland
Retrograde ureteroscopy
586.1
39.1
36
*
130
Kela drug reimbursment
Malignant tumour
+∞
38.2
34
*
D41.2
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Ureter
+∞
35.8
32
*
N13.3
ICD-10 Finland
Other and unspecified hydronephrosis
101.2
35.3
37
6
KCD02
NOMESCO Finland
Transurethral resection of bladder
438.0
31.9
30
*
KAC20
NOMESCO Finland
Nephroureterectomy
+∞
31.0
28
*
C67.9
ICD-10 Finland
Malignant neoplasm: Bladder, unspecified
+∞
27.5
25
*
KBV02
NOMESCO Finland
Cystoscopic insertion of stent into ureter
106.6
22.9
24
*
KAC21
NOMESCO Finland
Percutaneous endoscopic nephroureterectomy
+∞
22.9
21
*
H02AB02
ATC
dexamethasone; systemic
142.6
21.6
22
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
20.6
19
*
KCD05
NOMESCO Finland
Excision of bladder lesion during urinary tract endoscopy with photodynamic diagnosis (PDD)
236.2
19.3
19
*
D41.4
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Bladder
118.3
18.3
19
*
TPH07
NOMESCO Finland
Cathetrisation of artery
7.6
17.3
31
58
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
17.2
16
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
17.2
16
*
Z51.5
ICD-10 Finland
Palliative care
21.1
16.4
24
15
A04AA02
ATC
granisetron; systemic, transdermal
+∞
16.1
15
*
UKC05
NOMESCO Finland
Cystoscopy and bladder biopsy
95.3
15.1
16
*
A03FA01
ATC
metoclopramide; systemic, rectal
6.6
14.8
30
63
WZC00
NOMESCO Finland
Treatment plan or consultation
5.6
14.6
41
116
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
6.8
14.2
27
53
WX408
NOMESCO Finland
General anesthesy, balanced
5.6
14.0
36
94
JN4AD
NOMESCO Finland
Body CT examination
12.8
13.8
25
26
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
15.6
13.5
22
18
WX402
NOMESCO Finland
General anaesthesia
6.3
13.4
28
60
C65
ICD-10 Finland
Malignant neoplasm of renal pelvis
+∞
12.8
12
*
KH1BT
NOMESCO Finland
Urinary tract cathetrisation with X-ray guidance
+∞
12.8
12
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
149.6
12.8
13
*
WX302
NOMESCO Finland
Thoracal epidural anesthesy
19.9
12.3
18
11
TKC20
NOMESCO Finland
Catheterisation of bladder
7.1
12.1
21
37
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
11.0
11.9
23
27
KBV12
NOMESCO Finland
Transluminal endoscopic removal of stent from ureter
136.4
11.7
12
*
ZXE20
NOMESCO Finland
More than three and less than five hours
5.5
11.6
28
68
XF603
NOMESCO Finland
Direct intraarterial blood pressure measurement
25.2
11.1
15
7
XX3DW
NOMESCO Finland
Time consuming IT work
13.7
10.6
18
16
C67.2
ICD-10 Finland
Malignant neoplasm: Lateral wall of bladder
+∞
10.6
10
*
A04AA01
ATC
ondansetron; systemic, rectal
17.3
10.5
16
11
N02AA05
ATC
oxycodone; systemic
5.0
10.4
28
74
B01AB10
ATC
tinzaparin; parenteral
9.7
10.3
21
27
B01AB05
ATC
enoxaparin; parenteral
4.1
10.1
45
175
JN4BD
NOMESCO Finland
Extensive body CT
9.5
9.8
20
26
KCD32
NOMESCO Finland
Cystoscopic destruction of tumour of bladder
111.0
9.6
10
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
9.5
9
*
116
Kela drug reimbursment
Prostate cancer
+∞
9.5
9
*
KBD00
NOMESCO Finland
Partial excision of ureter
+∞
9.5
9
*
UKA02
NOMESCO Finland
Retrograde ureteronephroscopy
+∞
9.5
9
*
KH1AD
NOMESCO Finland
CT of urinary organs
13.5
9.5
16
14
ZXE10
NOMESCO Finland
More than one and less than three hours
3.8
9.1
48
206
ZXE00
NOMESCO Finland
One hour or less
3.8
9.1
51
228
JN4CD
NOMESCO Finland
Very extensive body CT
22.7
8.7
12
6
WZC30
NOMESCO Finland
Teaching
4.9
8.7
22
55
KC1GB
NOMESCO Finland
Cystography with X-ray
+∞
8.5
8
*
KBJ10
NOMESCO Finland
Cutaneous ureteroenterostomy
+∞
8.5
8
*
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
+∞
8.5
8
*
J01MA02
ATC
ciprofloxacin; systemic
3.6
8.4
54
260
KH1CD
NOMESCO Finland
Very extensive urinary tract ultrasound examination
36.9
8.3
10
*
KBV15
NOMESCO Finland
Cystoscopic change of ureteral stent
49.3
7.9
9
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
86.8
7.5
8
*
KBH20
NOMESCO Finland
Replantation of ureter
86.8
7.5
8
*
N13.1
ICD-10 Finland
Hydronephrosis with ureteral stricture, not elsewhere classified
+∞
7.4
7
*
L02AE02
ATC
leuprorelin; implant, parenteral
+∞
7.4
7
*
A79
ICPC
Malignancy NOS
+∞
7.4
7
*
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
3.6
7.3
31
113
J01EA01
ATC
trimethoprim; systemic
3.4
6.9
35
142
XKD00
NOMESCO Finland
Uroflowmetry
3.5
6.5
28
102
R4110
NOMESCO Finland
Physiotherapy
3.3
6.5
34
140
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
74.8
6.5
7
*
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
+∞
6.3
6
*
L03AA02
ATC
filgrastim; parenteral
+∞
6.3
6
*
KBV00
NOMESCO Finland
Insertion of stent into ureter
+∞
6.3
6
*
KBB00
NOMESCO Finland
Biopsy of ureter
+∞
6.3
6
*
A04AD12
ATC
aprepitant; systemic
+∞
6.3
6
*
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
+∞
6.3
6
*
TPH04
NOMESCO Finland
Cathetrisation of vein
3.4
6.2
29
111

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
60
29
57.61
86.94
6.0
1.9
—
—
—
0
0
27
41
8.91
18.15
2.0
1.1
—
—
—
0
0
51
176
5.26
14.31
3.5
1.5
—
—
—
0
0
57
223
5.09
13.49
6.3
3.4
—
—
—
0
0
55
213
4.93
13.09
8.3
3.2
492.54
362.62
e6/l
0.11
46
160
50
187
4.67
12.28
7.7
3.1
0.29
0.47
e6/l
0.46
43
132
57
241
4.59
11.76
9.2
4.0
152.21
91.53
e6/l
0.49
48
170
42
145
4.49
11.29
5.9
2.4
4.69
5.38
e6/l
0.17
37
125
22
45
6.11
10.91
9.9
6.7
—
—
—
0
0
47
181
4.26
10.82
7.5
3.0
—
—
—
0
0
40
145
4.11
9.86
5.4
2.9
458.94
530.09
mosm/kgh2o
1.84
34
115
30
88
4.57
9.80
10.0
4.1
105.97
104.25
mmol/l
1.15
30
88
20
30
8.21
8.98
10.9
8.3
—
—
—
0
0
44
181
3.74
8.87
3.3
1.9
—
—
—
0
0
18
37
5.80
8.78
10.9
5.7
0.73
1.51
%
3.21
18
37
18
37
5.80
8.78
10.9
5.6
0.33
0.71
%
4.22
18
37
46
200
3.60
8.43
6.4
3.9
—
—
—
0
0
65
354
3.85
8.34
8.6
5.0
1.20
1.21
mmol/l
0.62
58
299
28
89
4.08
8.09
5.1
2.7
0.82
0.82
mmol/l
0.12
28
79
16
20
9.43
8.00
1.7
1.2
—
—
—
0
0
26
81
4.08
7.69
9.3
5.4
-1.93
2.00
mmol/l
3.56
21
66
59
327
3.24
6.86
10.3
3.7
9.04
11.54
umol/l
3.11
59
301
72
463
3.55
6.26
8.9
4.6
—
—
—
0
0
43
208
3.00
6.20
5.7
3.6
7.39
7.40
ph
0.50
11
34
59
357
2.82
5.37
27.5
17.4
1.26
1.47
inr
0.99
21
104
28
114
3.09
5.36
8.6
3.2
0.83
1.61
e6/l
0.56
20
59
58
348
2.80
5.36
12.5
5.6
4.19
4.47
e9/l
0.40
47
296
6
6
10.57
3.55
1.2
1.3
—
—
—
0
0
16
60
3.02
3.44
3.3
2.1
4.97
6.72
umol/l
0.71
16
53
46
288
2.19
3.36
4.7
5.3
2.65
3.08
%
0.55
41
256
48
306
2.19
3.35
4.6
5.0
0.67
0.61
e9/l
0.54
38
261
48
308
2.17
3.28
4.6
5.0
0.04
0.04
e9/l
0.54
40
263
8
15
5.73
3.27
6.3
3.1
—
—
—
0
0
26
130
2.39
3.22
3.2
2.2
2.49
2.43
mmol/l
0.94
19
108
48
313
2.12
3.09
4.7
5.1
1.55
1.79
e9/l
0.58
39
269
79
633
2.76
3.01
29.6
14.5
48.79
26.84
mg/l
3.34
73
485
50
335
2.08
2.96
6.0
4.2
0.00
0.00
estimate
-0.00
14
56
48
321
2.04
2.82
4.6
5.0
0.18
0.20
e9/l
0.25
39
271
49
332
2.02
2.76
8.0
5.6
0.00
0.00
estimate
-0.00
12
49
14
56
2.77
2.68
4.1
3.0
—
—
—
0
0
49
336
1.98
2.63
6.2
4.0
0.00
0.00
estimate
-0.00
13
47
21
106
2.27
2.51
1.9
1.5
30.08
30.23
s
0.04
21
100
41
273
1.91
2.33
5.2
5.6
—
—
—
0
0
6
13
4.85
2.31
2.0
3.5
—
—
—
0
0
14
62
2.48
2.20
6.5
1.6
388.71
386.81
nmol/l
0.01
14
54
5
10
5.21
2.10
1.4
2.4
51.00
66.85
%
—
5
10
10
38
2.83
2.08
6.4
4.4
24.00
25.84
mmol/l
—
10
38
78
657
2.23
2.06
27.3
14.0
—
—
—
0
0
39
266
1.81
1.99
19.8
9.2
0.00
0.00
e9/l
0.50
26
215
6
16
3.93
1.97
6.3
1.7
16.50
13.33
u/ml
—
6
9
20
110
2.05
1.92
2.2
2.3
10.38
13.23
umol/l
1.13
20
98
29
186
1.82
1.78
6.9
3.6
—
—
—
0
0
10
43
2.48
1.65
1.5
1.3
—
—
—
0
0
27
174
1.78
1.62
7.5
4.3
0.00
0.00
estimate
—
8
48
7
26
2.83
1.61
5.6
2.7
—
—
—
0
0
33
230
1.68
1.49
4.8
4.2
—
—
—
0
0
9
40
2.38
1.45
1.6
1.4
—
—
—
0
0
79
695
1.97
1.44
43.6
20.8
249.09
236.59
e9/l
0.73
74
676
16
90
1.94
1.44
1.4
2.3
1.79
1.55
%
0.50
16
77
79
696
1.96
1.42
45.6
20.7
37.14
39.77
%
4.55
72
636
79
696
1.96
1.42
43.7
20.8
4.21
4.45
e12/l
3.87
74
670
79
696
1.96
1.42
43.7
20.8
7.20
6.75
e9/l
1.26
74
672
7
29
2.53
1.42
1.0
1.2
—
—
—
0
0
21
132
1.77
1.35
1.4
1.3
—
—
—
0
0
16
95
1.83
1.23
2.4
2.5
2.06
2.23
g/l
0.35
16
84
5
19
2.72
1.23
1.0
1.3
—
—
—
0
0
5
20
2.58
1.16
5.2
2.3
—
—
—
0
0
7
34
2.14
1.05
1.6
2.0
0.63
0.56
%
—
7
34
7
36
2.02
0.99
1.6
2.1
0.77
0.95
%
—
7
36
56
473
1.47
0.98
4.7
4.3
—
—
—
0
0
75
673
1.62
0.98
42.3
17.0
113.96
84.39
umol/l
3.63
75
673
10
55
1.92
0.96
8.7
3.8
—
—
—
0
0
20
137
1.59
0.94
9.3
4.5
—
—
—
0
0
38
302
1.44
0.90
2.0
2.1
97.01
96.15
pmol/l
0.03
18
140
10
57
1.85
0.87
1.5
1.2
—
—
—
0
0
10
57
1.85
0.87
4.3
4.0
—
—
—
0
0
39
320
1.38
0.74
3.6
3.9
49.90
59.41
ng/l
0.22
33
245
21
154
1.47
0.73
4.6
4.0
—
—
—
0
0
12
77
1.64
0.73
3.2
2.6
—
—
—
0
0
5
26
1.97
0.72
1.2
1.1
—
83.52
—
0
9
7
43
1.68
0.68
3.0
1.9
—
—
—
0
0
22
168
1.41
0.63
2.1
2.5
366.24
8193.75
umol/l
1.03
17
139
22
169
1.40
0.61
2.2
2.6
0.66
0.67
ug/l
0.03
14
121
8
53
1.56
0.60
3.6
1.4
—
—
—
0
0
28
230
1.31
0.51
1.9
3.1
6.36
7.27
mmol/l
0.81
22
187
30
249
1.30
0.51
2.7
3.8
5.27
7.78
mg/mmol
0.54
24
150
12
85
1.47
0.50
1.7
1.8
—
—
—
0
0
5
82
0.59
0.48
1.2
1.5
—
—
—
0
0
8
56
1.47
0.44
1.5
1.3
—
—
—
0
0
20
161
1.31
0.41
7.2
4.7
1.02
1.01
kg/l
—
6
26
0
17
0.00
0.41
0.0
1.2
—
0.24
—
0
17
0
18
0.00
0.40
0.0
1.3
—
1.06
—
0
18
5
35
1.45
0.40
1.0
1.2
—
—
—
0
0
7
53
1.35
0.31
3.0
2.8
—
—
—
0
0
15
183
0.78
0.31
3.5
3.8
—
—
—
0
0
63
592
1.20
0.30
5.6
4.7
2.05
1.97
mu/l
0.14
58
515
27
236
1.20
0.29
1.9
3.1
23.18
357.78
mg/l
0.61
20
141
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
6
49
1.24
0.20
2.0
1.3
—
—
—
0
0
12
100
1.23
0.19
1.9
1.6
—
—
—
0
0
6
75
0.79
0.16
1.2
1.2
—
807.62
—
0
21
24
221
1.12
0.12
1.6
2.1
336.12
227.00
u/l
0.22
24
210
5
45
1.12
0.10
3.0
2.6
6.22
3.20
e9/l
—
5
31
61
627
0.92
0.09
4.0
4.9
4.36
4.42
mmol/l
0.17
54
570
15
136
1.12
0.09
1.5
1.5
1.76
1.54
mg/l
—
10
95
63
645
0.93
0.08
4.6
5.5
2.45
2.56
mmol/l
0.46
57
580
65
635
1.08
0.08
5.2
5.2
6.14
6.15
mmol/l
0.02
57
559
61
621
0.95
0.04
3.9
4.9
1.36
1.46
mmol/l
0.92
54
556
61
600
1.05
0.03
3.5
4.3
1.33
1.19
mmol/l
1.03
53
530
62
618
1.01
0.00
7.3
6.9
41.91
41.25
mmol/mol
0.23
56
556
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.8
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
5.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
10
100
1.00
-0.00
2.3
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
2.97
—
0
7
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

Relationships between endpoints

↥

Index endpoint: C3_URETER – Malignant neoplasm of ureter

GWS hits: -

This endpoint is excluded from FinRegistry analyses (omitted endpoint).